Recombinant Human Complement Component C5a, Tag Free, 50 µg

Background
Human Complement Component C5a (C5a) is also known as C5,and is a protein fragment released from complement component C5.,is a potent chemotactic factor for human peripheral blood neutrophils and monocytes, and is believed to play an important role in a number of inflammatory conditions. There are several functions in the below: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is effective leukocyte chemoattractants, causing the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing avidity for white blood cell integrins and upregulating the Lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator, and seems to be a key factor in the development of pathology of many inflammatory diseases involving the complement system; C5a modulates balance between activating versus inhibitory IgG Fc receptors on leukocytes, thereby enhancing autoimmune response.

Source
Recombinant Human Complement C5a, Tag Free (C5A-H5116) is expressed from E.coli cells. It contains AA Leu 679 - Arg 751 (Accession # P01031).
Predicted N-terminus: Met

Molecular Characterization
This protein carries no "tag"
The protein has a calculated MW of 8.3 kDa. The protein migrates as 10-12 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "The complement C3a and C5a signaling in renal diseases: a bridge between acute and chronic inflammation"
Buelli, Imberti, Morigi
Nephron (2024)
(2) "C5a-C5aR1 axis controls mitochondrial fission to promote podocyte injury in lupus nephritis"
Ye, Chen, Guo et al
Mol Ther (2024)
(3) "Active Immunotherapy for C5a-mediated Inflammation Using Adjuvant-free Self-Assembled Peptide Nanofibers"
Hainline, Haddad, Gilpin et al
Acta Biomater (2024)
Showing 1-3 of 5251 papers.